Alzheimer’s
disease (AD) is characterized by extracellular deposition of amyloid
plaques, which are predominantly composed of amyloid-β (Aβ)
peptide derived from amyloid precursor protein (APP) cleavage. APP
interacts with tropomyosin receptor kinase A, a neurotrophic receptor
associated with gangliosides and mediating neuronal survival and differentiation
through the extracellular signal-regulated protein kinase (ERK) pathway.
The ganglioside Hp-s1’s analogue Hp-s1A exerts neuritogenic
activity; however, its effect on AD pathology remains unknown. To
test the hypothesis that Hp-s1A is a potential candidate to treat
AD, we established the AD-modeled cell line by expressing human Swedish
and Indiana APP gene (APP-Swe/Ind) in N2a mouse neuroblastoma cells.
The cells were treated with Hp-s1A or monosialoganglioside GM1 for
comparison. The AD model cells expressing APP-Swe/Ind exhibited a
significant reduction in viability, as well as neurite outgrowth rate,
in comparison to the control cells expressing APP-695. APP C-terminal
fragment-β (CTFβ) and Aβ42 were increased in the
AD cell lysates and the culture media, respectively. With the treatment
of either Hp-s1A or GM1 at 1 μM, the AD model cells showed a
significant increase in viability; however, only Hp-s1A reduced CTFβ
levels in these cells. Further analysis of the culture media revealed
that Hp-s1A also reduced Aβ42 production from AD model cells.
The phosphorylation of ERK was elevated and the neurite outgrowth
rate was restored with Hp-s1A treatment. In conclusion, the ganglioside
analogue Hp-s1A inhibited amyloidogenic processing of APP and promoted
neurotrophic activity and survival of AD model cells. Hp-s1A has great
potential in AD therapeutic development.